All In Biotech

Drug Trial Radar · NCT03601078

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

312

Actual

Start

Dec 13, 2018

Primary completion

Jan 15, 2026

Study completion Jan 15, 2026

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), in participants with multiple myeloma (MM) having progressed within 18 months of initial treatment with autologous stem cell transplantation (ASCT) (Cohort 2a) and without ASCT (Cohort 2b) or, in participants with inadequate response post ASCT during initial treatment (Cohort 2c) and the efficacy and safety of bb2121 used in combination with lenalidomide maintenance in participants with suboptimal response post ASCT (Cohort 3). Approximately 248 participants will be enrolled into one of three cohorts. Cohort 1 (including cohort 1b) will enroll approximately 126 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2a will enroll approximately 39 MM subjects, with 1 prior anti-myeloma therapy including ASCT and with early relapse. Cohort 2b will enroll approximately 39 MM subjects with 1 prior anti-myeloma therapy not including ASCT and with early relapse. Cohort 2c will enroll approximately 30 MM subjects with inadequate response to ASCT during their initial anti-myeloma therapy. The cohorts will start in parallel and independently. Cohort 3 will enroll approximately 30 newly diagnosed multiple myeloma (NDMM) participants with suboptimal response to ASCT.

Conditions

  • Multiple Myeloma

Interventions

  • bb2121Biological

    bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

  • LenalomideDrug

    Specified dose on specified days

  • TalquetamabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)- Cohort 1Time frame: Up to approximately 5 years (Participants will transition to the long term follow-up (LTFU) study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)
  2. Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3Time frame: Up to approximately 5 years (Participants will transition to the LTFU study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)

Locations

25 sites in 6 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Scottsdale

    Scottsdale, Arizona

  • University Of California San Francisco Medical Center

    San Francisco, California

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • University Of Nebraska

    Omaha, Nebraska

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Mt Sinai Medical Center - NY

    New York, New York

  • Columbia University Medical Center/New York-Presbyterian Hospital

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • University Of Texas Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center The University of Texas

    Houston, Texas

  • Swedish Cancer Inst

    Seattle, Washington

  • Froedtert Hospital BMT Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Local Institution - 404

    Poitiers, France

  • Local Institution - 506

    Hamburg, Germany

  • Local Institution - 505

    Würzburg, Germany

  • Local Institution - 603

    Bologna, Italy

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Local Institution - 704

    Salamanca, Spain

  • Kings College Hospital NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.